ENSIGN GROUP, INC Q3 FY2026 earnings call

• Clinical Excellence: Ensign’s 'One Clinical' model integrates therapy and nursing as equal partners, resulting in CMS quality measure ratings 21% above state averages and survey results outperforming peers by 15%. Over 80% of skilled nursing operations earned 4-5 star CMS ratings.
• Employee Stability: Leadership retention is significantly stronger than industry norms, with RN retention rates 11% better and administrator turnover 45% lower than state averages, driven by the CAPLICO culture.
• Census and Mix Growth: Same-store occupancy reached 84.1% and transitioning facilities reached 86.1%. Skilled mix revenue increased by 10.7% (same-store) and 10.5% (transitioning), with Medicare days up 7.6% and managed care revenue up 9.1%.
• Acquisition Momentum: Since 2024, 122 new operations have been integrated. In Q3, 22 new operations were added across Florida, Colorado, Washington, and Texas, adding 2,373 skilled nursing beds.
• Success Stories: Decatur County Healthcare (TN) improved occupancy from 65% to 79% and EBIT by over 400% within two years. Bainbridge Island (WA) achieved zero deficiencies and high-performing CMS designation despite labor challenges.
• Real Estate Strategy: Standard Bear Healthcare REIT now owns 183 properties, with strong coverage ratios (EBITDAR to rent at 2.6x). The company actively pursues buying leased assets when landlords seek capital redeployment.

The transcript does not provide a breakdown of financial performance by specific product segment (e.g., Skilled Nursing vs. Independent Living) in absolute terms or revenue contribution percentages. The company reports consolidated GAAP revenue and adjusted revenue of $1.48 billion, an increase of 14.5% year-over-year. Standard Bear Healthcare REIT generated rental revenue of $47.7 million for the quarter.

• EPS Guidance Raised: Annual 2026 diluted EPS guidance increased to $7.94–$8.02 per share, up from the previous range of $7.75–$7.85.
• Revenue Guidance Raised: Lower end of annual revenue guidance raised to $5.89 billion; upper end maintained at $5.92 billion.
• Growth Context: The midpoint of the new EPS guidance implies a 21.5% increase over 2025 and 45.1% growth over 2024.
• Assumptions: Guidance assumes ~59.5 million diluted shares, a 25% tax rate, inclusion of Q4 closings, and excludes stock-based compensation and amortization of system implementation costs.

• Acquisition Integration Challenges: Recent acquisitions in Florida and Texas are described as 'very challenged' clinically, financially, and physically. These turnarounds are expected to take a year or more to become accretive contributors to earnings.
• Litigation Environment: Florida’s litigious environment was cited as a historical deterrent and remains a key risk factor for entry into that market.
• Reimbursement Variability: Performance may be impacted by variations in reimbursement systems, delays in state budgets, and general economic influences on census and staffing.
• Operational Execution: While management is confident, risks remain regarding the ability to consistently execute clinical transformations and retain leadership across a rapidly expanding portfolio.

Q: Ben Hendrix asked about unique risks in entering the Florida market, specifically regarding referral networks, regulation, and labor.

A: Barry Port noted that while Florida has a busy litigation environment and moderate regulatory difficulty, it offers a stable rate environment and good labor conditions. He emphasized that pre-entry groundwork laid by a seasoned leader and existing payer relationships allow Ensign to bypass typical ramp-up hurdles through one-off arrangements while proving clinical outcomes.

Q: David McDonald asked if the strong Q4 implied guidance suggests core business strength or if recent M&A deals like those in Texas are outperforming.

A: Barry Port clarified that Texas and Florida acquisitions are highly challenged turnarounds that will not be accretive until later, likely Q4 or beyond. Suzanne Snapper confirmed that the guidance relies heavily on the core business's continued strength, citing high same-store occupancy (84%) and elevated skilled mix as the primary drivers for the step-up in performance.

Q: Raj Kumar asked what supports the sustainability of high skilled mix (>32%) post-COVID and if M&A pace can exceed historic levels.

A: Barry Port attributed sustained high acuity to consistent clinical outcomes that build trust with hospitals and managed care plans, leading to referrals for complex cases. Chad Keetch stated that maintaining a pipeline of ~52 CEOs-in-training allows them to comfortably sustain 50-60 acquisitions annually, supported by strong deal flow and balance sheet capacity.

Q: AJ Rice asked about the sourcing diversity of deals (nonprofits vs. REITs) and opportunities to buy out leased properties as leases mature.

A: Chad Keetch reported that deal flow is abundant from all sources, including nonprofits and REITs. Regarding buyouts, he highlighted that lease maturities present steady opportunities; for example, they recently bought facilities from a public REIT and private family owners who sought to exit real estate ownership, leveraging their balance sheet to unlock equity and gain operational flexibility.